Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Sell
47
STAA Quote, Financials, Valuation and Earnings
Last price:
$19.25
Seasonality move
:
12.47%
Day range:
$18.77 - $19.47
52-week range:
$13.50 - $49.86
Dividend yield:
0%
P/E ratio:
49.73x
P/S ratio:
3.42x
P/B ratio:
2.72x
Volume:
865K
Avg. volume:
914.6K
1-year change:
-54.92%
Market cap:
$953.4M
Revenue:
$313.9M
EPS (TTM):
-$1.44
Analysts' Opinion
-
Consensus RatingStaar Surgical has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 10 Hold ratings, and 1 Sell rating.
-
Price Target DownsideAccording to analysts' consensus price target of $19.10, Staar Surgical has an estimated downside of -0.78% from its current price of $19.25.
-
Price Target UpsideAccording to analysts, the highest upside price target is $27.00 representing 40.26% upside increase from its current price of $19.25.
Fair Value
-
According to the consensus of 14 analysts, Staar Surgical has -0.78% downside to fair value with a price target of $19.10 per share.
STAA vs. S&P 500
-
Over the past 5 trading days, Staar Surgical has underperformed the S&P 500 by -6.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Staar Surgical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Staar Surgical revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Staar Surgical reported revenues of $42.6M.
Earnings Growth
-
Staar Surgical has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Staar Surgical reported earnings per share of -$1.10.
Enterprise value:
730.6M
EV / Invested capital:
2.09x
Price / LTM sales:
3.42x
EV / EBIT:
32.77x
EV / Revenue:
2.62x
PEG ratio (5yr expected):
3.88x
EV / Free cash flow:
-23.31x
Price / Operating cash flow:
41.12x
Enterprise value / EBITDA:
26.79x
Gross Profit (TTM):
$206.6M
Return On Assets:
-14.16%
Net Income Margin (TTM):
-25.47%
Return On Equity:
-17.97%
Return On Invested Capital:
-17.97%
Operating Margin:
-81.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $294.7M | $326.2M | $279.1M | $77.4M | $42.6M | |
| Gross Profit | $231.7M | $256.1M | $206.6M | $61M | $28M | |
| Operating Income | $34.5M | $23M | -$45.1M | -$2.3M | -$34.7M | |
| EBITDA | $39.1M | $28.3M | -$37.1M | -$1M | -$32.4M | |
| Diluted EPS | $0.64 | $0.31 | -$1.44 | -$0.07 | -$1.10 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $223.5M | $273.9M | $312.9M | $365.7M | $326.5M | |
| Total Assets | $265.8M | $351.2M | $418.9M | $492.5M | $457.4M | |
| Current Liabilities | $36.1M | $41.2M | $47.1M | $62.7M | $68.4M | |
| Total Liabilities | $51.6M | $74.9M | $80M | $99.7M | $107.4M | |
| Total Equity | $214.2M | $276.3M | $338.9M | $392.8M | $350M | |
| Total Debt | $1.3M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $35.2M | $41.4M | -$11.7M | $21.7M | -$5.7M | |
| Cash From Investing | -$143.9M | $80.6M | -$40.1M | $16.2M | $35.4M | |
| Cash From Financing | $6M | $12.8M | $720K | $4.1M | -$948K | |
| Free Cash Flow | $16.8M | $20.9M | -$31.3M | $16.5M | -$7.2M | |
STAA
Sector
Market Cap
$953.4M
$34.2M
Price % of 52-Week High
38.61%
43.73%
Dividend Yield
0%
0%
Shareholder Yield
0.18%
-0.66%
1-Year Price Total Return
-54.92%
-41.71%
Beta (5-Year)
0.652
0.657
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$19.05
200-day SMA
Sell
Level
$25.61
Bollinger Bands (100)
Sell
Level
16.66 - 22.7
Chaikin Money Flow
Buy
Level
32.7M
20-day SMA
Buy
Level
$18.61
Relative Strength Index (RSI14)
Buy
Level
55.81
ADX Line
Buy
Level
23.87
Williams %R
Neutral
Level
-48.5313
50-day SMA
Buy
Level
$17.77
MACD (12, 26)
Buy
Level
0.39
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
37.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.4533)
Buy
CA Score
(Annual)
Level (0.9748)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-2.5106)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Stock Forecast FAQ
In the current month, STAA has received 3 Buy ratings 10 Hold ratings, and 1 Sell ratings. The STAA average analyst price target in the past 3 months is $19.10.
-
Where Will Staar Surgical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Staar Surgical share price will drop to $19.10 per share over the next 12 months.
-
What Do Analysts Say About Staar Surgical?
Analysts are divided on their view about Staar Surgical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Staar Surgical is a Sell and believe this share price will rise from its current level to $13.00.
-
What Is Staar Surgical's Price Target?
The price target for Staar Surgical over the next 1-year time period is forecast to be $19.10 according to 14 Wall Street analysts, 3 of them rate the stock a Buy, 1 rates the stock a Sell, and 10 analysts rate the stock a Hold.
-
Is STAA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Staar Surgical is a Hold. 10 of 14 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of STAA?
You can purchase shares of Staar Surgical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Staar Surgical shares.
-
What Is The Staar Surgical Share Price Today?
Staar Surgical was last trading at $19.25 per share. This represents the most recent stock quote for Staar Surgical. Yesterday, Staar Surgical closed at $19.25 per share.
-
How To Buy Staar Surgical Stock Online?
In order to purchase Staar Surgical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Mobileye Might Be Wall Street’s Next Big Surprise
The trend to automate vehicles started long ago when adding…
Why Is Rigetti Stock Going Up?
Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
99
SOC alert for May 20
Sable Offshore [SOC] is down 0.79% over the past day.
Buy
52
RGC alert for May 20
Regencell Bioscience Holdings [RGC] is up 31.16% over the past day.
Sell
40
GWLIF alert for May 20
Great-West Lifeco [GWLIF] is up 13.42% over the past day.
